BioBridgeX
Log inCompare quotes
Indication

Oncology CRO and CDMO vendors

Free for buyersNeutral marketplace
Quick answer

Outsourcing an oncology program means sourcing CRO and CDMO partners for tumor biology and target work, in vivo efficacy in xenograft, syngeneic, and PDX models, DMPK and tox, then GCP clinical operations measuring endpoints like ORR, PFS, and OS. It spans small molecules, antibodies, ADCs, and CAR-T. On BioBridgeX, buyers compare qualified oncology suppliers in one place, free for buyers, with a flat 2% supplier fee.

Oncology CRO and CDMO vendors on BioBridgeX

We are qualifying and publishing Oncology CRO and CDMO vendors now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What kind of CRO work does an oncology program need?

Oncology is the most crowded therapeutic area in drug development, and the outsourcing map is wide because the science is. Early on you need tumor biology and target validation: confirming the target actually drives the cancer you care about, profiling expression across tumor types, and running CRISPR or knockdown work to show dependency. From there a program moves into the part of oncology preclinical work that almost everyone outsources, the in vivo efficacy studies, because few biotechs keep a colony of immunodeficient mice and a working bank of tumor models in-house.

The model you pick is not a detail, it is the whole readout. Cell-line-derived xenografts in immunodeficient mice are the fast, cheap workhorse for showing a small molecule or antibody shrinks a tumor. Syngeneic models in immunocompetent mice are what you need for immuno-oncology, because an anti-PD-1 or a bispecific does nothing without a working immune system to engage. Patient-derived xenografts (PDX) keep the original tumor's heterogeneity and are closer to the clinic but slower and pricier. Humanized-mouse and orthotopic models, plus metastasis and patient-derived organoid work, fill in the harder questions. A CRO that runs your specific model with historical control data is worth far more than one spinning it up for the first time on your budget.

Then come the standard preclinical workstreams, read through an oncology lens: DMPK and ADME, dose-range-finding, and tox, where the safety bar differs from other areas because cytotoxic and targeted oncology agents are often allowed a narrower therapeutic window and a higher tolerated toxicity. Biomarker and companion-diagnostic work tends to start earlier here than anywhere else, since modern oncology approvals lean on patient selection. On the clinical side the work is GCP clinical operations built around oncology endpoints, overall response rate (ORR) by RECIST, progression-free survival (PFS), overall survival (OS), and duration of response, run through specialist sites, central imaging and independent review, and safety reporting. The modality range is enormous: small molecules and kinase inhibitors, monoclonal and bispecific antibodies, antibody-drug conjugates (ADCs), CAR-T and other cell therapies, radioligands, and cancer vaccines, each of which changes which suppliers can actually do the work.

How do you choose a CRO for oncology?

The logo on the contract matters less than whether the team has run your exact kind of program before. Oncology is broad enough that genuine expertise is narrow: a CRO that is excellent at solid-tumor xenografts may have never touched a hematologic disseminated model or a CAR-T persistence study. Score two or three suppliers against the same written scope, and weight relevant, recent, in-modality experience above the headline quote. Below are the filters that actually separate a clean program from a frustrating one.

  • Therapeutic-area and tumor-type fit: ask specifically about the cancer type and modality you are working in (solid versus heme, the indication, immuno-oncology versus cytotoxic versus targeted), not generic oncology experience.
  • Relevant models or patient access: for preclinical, confirm the specific xenograft, syngeneic, PDX, or orthotopic model is already validated in-house with historical control data. For clinical, ask about access to oncology investigator sites and realistic enrollment in your indication, which is the usual rate-limiter.
  • Regulatory and quality track record: GLP for the pivotal tox, GCP and a clean inspection history for clinical work, and experience with the regulatory pathway your program is aiming at, including any breakthrough, fast track, or accelerated-approval context.
  • Endpoint and data quality: for clinical, how they handle RECIST assessment, central imaging, blinded independent review, and CDISC-conformant data. For preclinical, clean tumor-growth data, honest reporting of the cohorts that failed, and clear statistics.
  • Capacity and timeline: a strong lab booked solid for months can be slower than a good lab with an open slot. Confirm current queue, report turnaround (not just bench time), and how change orders are priced when a study or a cohort slips.
  • Biomarker and CDx capability: if your program depends on patient selection, confirm the supplier can run the biomarker assay or companion-diagnostic development you will need, ideally the same team that carries it toward the clinic.

Frequently asked questions

Which CRO services does an oncology program use most?
In preclinical oncology the heaviest outsourcing is in vivo efficacy work, because tumor models are expensive to maintain in-house. That means xenograft, syngeneic, PDX, and orthotopic studies measuring tumor growth inhibition, alongside DMPK, dose-range-finding, and toxicology. Biomarker and companion-diagnostic work often starts early. On the clinical side, oncology programs lean on GCP clinical operations, oncology-experienced investigator sites, central imaging with RECIST review, biostatistics, and pharmacovigilance. The exact mix depends on your modality and whether you are at the discovery, preclinical, or clinical stage.
What is the difference between xenograft, syngeneic, and PDX models?
They answer different questions. Cell-line-derived xenografts grow human tumor cells in immunodeficient mice and are the fast, lower-cost standard for showing a small molecule or antibody shrinks a tumor. Syngeneic models use mouse tumors in immunocompetent mice, which you need for immuno-oncology because a checkpoint inhibitor requires a working immune system to do anything. Patient-derived xenografts (PDX) implant a patient's actual tumor and preserve its heterogeneity, making them more clinically predictive but slower and more expensive. Choosing the wrong model gives you a clean result that means nothing for your mechanism.
How do you choose a CRO for an immuno-oncology program specifically?
Immuno-oncology narrows the field fast. You need a supplier with immunocompetent syngeneic and humanized-mouse models, validated and running in-house with historical control data, plus the immunophenotyping and flow cytometry to read out immune-cell changes, not just tumor volume. Ask which IO mechanisms they have actually run (checkpoint, bispecific, CAR-T, myeloid-targeting) and to see comparable data. A generalist oncology CRO that only does immunodeficient xenografts cannot properly test a mechanism that depends on the immune system, no matter how good the price looks.
What clinical endpoints matter for an oncology trial?
The core oncology endpoints are overall response rate (ORR) measured by RECIST, progression-free survival (PFS), overall survival (OS), and duration of response. OS is the gold standard for full approval but takes the longest to read out, while ORR and PFS often support accelerated or earlier approval depending on the setting. Your CRO needs to handle RECIST tumor assessment consistently, usually through central imaging and blinded independent review, because endpoint integrity is exactly what regulators scrutinize in an oncology submission.
Why does patient selection and companion-diagnostic work start so early in oncology?
Modern oncology approvals frequently depend on a biomarker that identifies which patients respond, so the diagnostic and the drug are developed in parallel. If your mechanism targets a specific mutation, expression level, or pathway, you want the biomarker assay defined in preclinical work and carried into the clinic, ideally by a team that can take it through companion-diagnostic development. Leaving patient selection until late forces expensive retrofitting and can sink an otherwise promising program in a trial that enrolled the wrong patients.
How does sourcing oncology CRO and CDMO services through BioBridgeX work?
BioBridgeX is a neutral marketplace, not a lab, so it has no incentive to steer your oncology work toward a preferred site. You describe the program (the tumor type, modality, the specific models or clinical functions, and the stage) and get matched with qualified suppliers you can compare side by side on capability, experience, and transparent quotes. It is free for buyers, suppliers pay a flat 2% fee, and when an oncology program spans several suppliers (a tumor-model CRO, a DMPK lab, a clinical operations group) you compare them and contract directly with the ones you choose, in one place.

Source Oncology work with one contract

Compare transparent quotes from qualified Oncology CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes